MDACC Study No:2013-0564 ( NCT No: NCT01925612)
Title:A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) or RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone as front-line therapy in patients with diffuse large B-cell lymphoma (DLBCL)
Principal Investigator:Luis E. Fayad
Treatment Agent:Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if brentuximab vedotin,
when combined with 1 of 2 different types of standard chemotherapy (described
below), can help to control DLBCL. The safety of these drug combinations will
also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Brentuximab Vedotin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Luis E. Fayad
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults